. Author manuscript; available in PMC: 2024 Aug 12.

Published in final edited form as: Infect Genet Evol. 2016 May 21;46:269–278. doi: 10.1016/j.meegid.2016.05.029

Table 2.

Drug resistance mutations present in HIV-1-infected persons who inject drugs in Bulgaria.

Patient Code^a	Gender	Region	Subtype	Naïve/HAART^b	Year of diagnosis	Year of specimen collection	Antiretroviral mutations^c
Patient Code^a	Gender	Region	Subtype	Naïve/HAART^b	Year of diagnosis	Year of specimen collection	NRTI	NNRTI	PI
06BG481	F	Silistra	B	HAART	2004	2006	M41L, D67N, K70R, M184V, T215F, K219E	None	None
11BG606	M	Sofia	B	HAART	2006	2011	M184V	None	None
10BG704	M	Plovdiv	CRF02_AG	HAART	2007	2010	None	K103N	None
11BG769	M	Plovdiv	CRF02_AG	HAART	2007	2011	M184V	Y188L	None
11BG892	M	Peshtera	CRF01_AE	Naïve	2008	2011	None	G190E	None
11BG1012	M	Plovdiv	CRF02_AG	HAART	2009	2011	None	Y181C	None
11BG1023	M	Sofia	CRF01_AE	HAART	2009	2011	None	K103N	None
11BG 1362	M	Plovdiv	CRF02_AG	Naïve	2011	2011	None	K103N	None

Drug resitance results for patients with codes in bold italics were reported previously (Alexiev et al., 2015).

HAART, highly active antiretroviral therapy.

NRTI, nucleotide reverse transcriptase inhibitors; NNRTI, non-nucleotide reverse transcriptase inhibitors; PI, protease inhibitors.